# Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar

> **NCT03662022** · PHASE3 · COMPLETED · sponsor: **Institute of Tropical Medicine, Belgium** · enrollment: 144000 (actual)

## Conditions studied

- Leprosy

## Interventions

- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT03662022
- **Lead sponsor:** Institute of Tropical Medicine, Belgium
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-02
- **Primary completion:** 2023-01-17
- **Final completion:** 2023-01-17
- **Target enrollment:** 144000 (ACTUAL)
- **Last updated:** 2025-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662022, "Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03662022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*